{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ragon BK"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["2746-2757"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10275699"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(12)"],"pubmed_abstract":["The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials using auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM). We evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in patients with MM after auto-HSCT using CIBMTR registry data. Adult patients with MM who underwent first auto-HSCT in the United States with melphalan conditioning r"],"journal":["Blood advances"],"pubmed_title":["Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis."],"pmcid":["PMC10275699"],"funding_grant_id":["P30 CA008748","U24 CA076518","UL1 TR001863","P50 CA186781"],"pubmed_authors":["Qazilbash MH","Munshi PN","Shah N","Hashmi S","Nieto Y","D'Souza A","Vesole DH","Mian H","Badawy SM","Al Hadidi S","Shah MV","George G","Miller KC","Kharfan-Dabaja MA","Battiwalla M","Saad A","Solh M","Nishihori T","Estrada-Merly N","Gowda L","Murthy HS","Kumar SK","de Lima M","Majhail NS","Patel SS","Ragon BK","Afrough A","Banerjee R","Lekakis LJ","Aljurf M","Hildebrandt GC","Strouse C","Pawarode A","Holmberg LA","Anderson LD","Usmani SZ","Kaur G","Lee CH","Abid MB","Dholaria B","Gergis U","Wirk B"],"additional_accession":[]},"is_claimable":false,"name":"Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.","description":"The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials using auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM). We evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in patients with MM after auto-HSCT using CIBMTR registry data. Adult patients with MM who underwent first auto-HSCT in the United States with melphalan conditioning r","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2026-07-14T21:54:28.327Z","creation":"2024-12-04T07:31:50.98Z"},"accession":"S-EPMC10275699","cross_references":{"pubmed":["36827681"],"doi":["10.1182/bloodadvances.2022009138"]}}